What's Happening?
Silexion Therapeutics has announced the initiation of Good Manufacturing Practice (GMP) clinical supply manufacturing for its RNA interference therapy, SIL204, targeting KRAS-driven pancreatic cancer. The company is collaborating with Catalent at its European
center to produce the drug for an upcoming Phase 2/3 trial. The trial has received approval from the Helsinki Ethics Committee of Tel Aviv Sourasky Medical Center, marking a significant step towards clinical testing. This development is part of Silexion's efforts to advance its siRNA therapy, which aims to silence mutated KRAS oncogenes, a common driver in human cancers.
Why It's Important?
The advancement of SIL204 into clinical trials represents a significant milestone in the fight against pancreatic cancer, a disease with limited treatment options and poor prognosis. By targeting KRAS mutations, Silexion's therapy could offer a new avenue for treatment, potentially improving outcomes for patients with this aggressive cancer. The collaboration with Catalent and the approval from a leading Israeli medical center underscore the therapy's scientific and regulatory progress. Success in these trials could pave the way for broader application of RNA interference therapies in oncology.
What's Next?
With the GMP manufacturing underway, Silexion is preparing for the first patient dosing in the Phase 2/3 trial. The company is also awaiting further regulatory approvals, including a Clinical Trial Application review in Germany. The trial will evaluate the efficacy of SIL204 in combination with standard chemotherapy, using a dual-route administration strategy. As the trial progresses, Silexion will continue to engage with regulatory bodies and refine its manufacturing processes to ensure compliance and efficacy.
